Annual Next Gen Immuno-Oncology Congress

Paris, France   October 25-27, 2018

Theme: Immuno-Oncology: The Strategic Supernova in Cancer Today

Meetings Internationalofficially welcomes all the participants from all over the world to attend international conference on Annual Next Gen Immuno-Oncology Congress” Scheduled in Paris, France during Oct 25-27, 2018.This conference is Mainly accelerating  on Immuno-Oncology: The Strategic Supernova In Cancer Today This conference acquires a global platform for Oncologists, Doctors, Researchers, Surgeons, Physicians, Young Researchers, business Delegates to Exchange Ideas and knowledge.

Meetings International  provides a global platform for Medical, Biotech, Pharmaceutical and Healthcare Professionals to Exchange Ideas, Knowledge and Networking at 100+ International Conferences. It supports broad scope research and peer review at a broad range of specialists around the world. The key strategic objective of Meetings International is to communicate science and medical research between academia and industry.   

Immuno Oncology Conference  gathering incorporates Plenary lectures, keynote lectures by famous personalities from around the world in addition to poster presentation, young researcher sessions, symposiums, workshop and Exhibitions. It focuses on a wide array of topics that include the following:  Immuno-Oncology studies, Cancer Biomarkers, Immune checkpoint inhibitors, Immune checkpoint inhibitors, Cancer ,Novel Approaches in Cancer & Tumor, Stem Cell Therapy, The current drugs available in immunotherapy (and combinations),.Immune Responses Against Tumors and Transplants, Evaluating response in Immunotherapy, Precision Genomics and Precision Medicine for Immuno Oncology, Cancer Immunotherapy, Technological developments of immuno oncology. Adoptive T cell therapy (ACT), Advances in cancer treatment,Tools and trends in Immuno-Oncology.

Why Paris?

Immuno-Oncology is the rapidly developing field of cancer bio therapeutics in Paris; in fact it that The guarantee of health insurance is the first reason why cancer experts around the world look to France as a model for cancer treatment and care. Another is that cancer care is well organized at the national and hospital levels. So the Immuno-Oncology 2018  is going to be held in France.

Paris, France's capital is a major European city and a global centre for art, fashion, and culture. Its 19th-century city scape is crisscrossed by wide boulevards and the River Seine. Beyond such landmarks as the Eiffel Tower and the 12th-century, Gothic Notre-Dame cathedral, the city is known for its cafe culture and designer boutiques along the Rue du Faubourg Saint-Honore.

Why to Attend:

It provide an international platform for discussion of present and future challenges in Immunology, Immuno Oncology education, continuing education and expertise meeting. World-leading health Immunologists, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research.

  • Sharpen your skills.
  • Meet experts and influencers face-to-face.
  • Learn in a new space,Network.
  • Explore new ways of working.
  • Get greater focus.
  • Learn new information from presenters.
  • Networking with new people within your field.
  • The ability to share your ideas and get immediate feedback from credible individuals.
  • To expand your knowledge and find solutions to problems.
  • To present your ideas and work to others.
  • Get out of Dodge and just have fun.

 

 

 

Track 1. Immuno-Oncology Studies:

The immune system is the body’s natural defence system. It is a collection of organs, cells and special molecules that helps protect you from infections, cancer and other diseases.Immuno-oncology therapies activate our immune system, making it able to recognise cancer cells and destroy them. Breast cancer is one of the major cancer type for which new immune –based cancer treatment are currently in development .Lung cancer surgery carries risks, including bleeding and infection. Advances in Immuno-oncology have given oncologists and their patient’s reason to be encouraged—the launch of immune checkpoint inhibitors and development of other immunotherapy assets for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer, represents great progress.

Immuno Oncology Conference Immuno Oncology Workshop Global Immuno Oncology Conference Immuno Oncology symposium Immuno Oncology Congress |   Immuno Oncology Seminar Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland 

Track 2. Cancer Biomarkers:

Biomarker refers to a substance (or) process that indicates the presence of cancer in the body. There are distinctive biomarkers used for prognosis, diagnosis and epidemiology like, genetic, and imaging biomarkers. A number of gene and protein based biomarkers have already been used at some point in patient care.

In cancer research and medicine, biomarkers are used in three primary ways:

  • To help diagnose conditions, as on account of recognizing beginning period diseases (Diagnostic)
  • To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)
  • To predict how well a patient will react to treatment (Predictive)

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 3. Immune Checkpoint Inhibitors:

Immunology-based treatment is quickly forming into a viable treatment alternative for an astonishing scope of diseases. We have learned in the course of the most recent decade that capable immunologic effector cells might be obstructed by inhibitory administrative pathways controlled by specific molecules often called "immune checkpoints”. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), customized cell demise 1 (PD-1), and modified cell passing ligand 1 (PD-L1). These inhibitors of resistant hindrance have exhibited broad action as single operators and in blends.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 4. Cancer Clinical Trials:

To developing new techniques to prevent, detect, and treat cancer. It is through clinical trials that researchers can determine whether new treatments are safe and effective and work better than current treatments. Cancer clinical trials have led to have prompted logical advances that have increased doctor’s understanding of how and why tumour’s develop and grow. This knowledge has helped doctors make progress in preventing cancer, diagnosing cancer, slowing or stopping the development of cancer, and finding cancers that have come back after treatment.

  • Treatment trials
  • Prevention trials
  • Screening trials
  • Quality-of-life/supportive care/palliative care trials
  • Signs & Symptoms
  • Diagnosis of CML
  • Risk factors
  • Treatment & Drugs

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 5.  Novel Approaches in Cancer & Tumor:

Immunotherapy incorporates several different treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to restore immune function in some manner.  This includes: Monoclonal antibodies, Immune checkpoint inhibitors, Therapeutic Cancer vaccines, cytokines, and other non-specific immunotherapies.

  • Revisiting Tumor Metabolism
  • Telomerase: A Target for Cancer Therapeutics
  • Molecular Cancer Therapeutics
  • Metabolomics in Novel Biomarker Discovery

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 6. Stem Cell Therapy:

Cancer stem cells (CSCs) is the cancer cells found inside tumors  that attributes related with typical undifferentiated organisms called which have the ability to offer  all cell types found in a particular cancer sample CSCs may produce tumors through the immature microorganism procedures of self-restoration and variety into different cell composes... Therefore, for improvement of survival and quality of life of cancer patients, development of specific therapies targeted at CSCs holds hope, particularly for patients with metastatic disease.

Induced pluripotent stem cells: iPSC are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state empowers the improvement of a boundless wellspring of a human cell required for helpful purposes.. For example, iPSC can be prodded into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukemia patient, or neurons to treat neurological disorders.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 7. The Current Drugs Available in Immunotherapy and combinations:

Multiple examples of immunotherapy combinations have been evaluated. Because tumors are heterogeneous and have different mechanisms through which they can evade the immune system, drugs inhibiting different underlying pathways may be more effective than one drug targeting one pathway. A major breakthrough in this direction has been the development of checkpoint inhibitors—typically mAbs that block the activity of immunosuppressive ligands released by many cancer cells. PD-1 and its ligands, as well as CTLA-4, have emerged as promising molecular targets for a range of cancers

  • Targeted Therapy
  • Immunotherapy
  • Malignant and non-malignant diseases
  • Stem cell transplantation
  • Gene Therapy
  • Angiogenesis Inhibitors
  • Bone marrow Transplantation
  • Induced Pluripotent Stem Cells
  • Technologies in Stem Cell Research

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 8. Immune Responses Against Tumors and Transplants:

Immunoediting induces choice for sure growth cells that loose dominant growth-specific antigens permitting the tumour to progress. Its 3 main phases: elimination, equilibrium and escape. Professionals within the field have hypothesized that ‘apoptotic necrobiosis is poorly immunogenic whereas death necrobiosis is actually immunogenic. Varied strains of human papillomavirus (HPV) are found to play a vital role within the development of cervical cancer. Organ transplantation may be a process during which associate organ is off from one body and placed within the body of a recipient, to exchange a broken or missing organ. Organs that are with success transplanted embrace the centre, kidneys, liver, lungs, pancreas, intestine, and thymus. Some organs, just like the brain, can't be transplanted.Medicine has applications in varied disciplines of medication, notably within the fields of organ transplantation, oncology, virology, medicine, parasitology, psychiatry, and medical specialty.

  • ABO-Incompatible Transplants
  • Immunologic Mechanisms of Rejection
  • Acute or Chronic Rejection
  • Blood Transfer

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 9. Evaluating Response in Immunotherapy:

Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a paradigm shift in the treatment of advanced-stage cancers. The promising anti tumor activity of monoclonal antibodies targeting the immune-checkpoint proteins CTLA-4, PD-1, and PD-L1 led to regulatory approvals of these agents for the treatment of a variety of malignancies. Patients might experience clinical benefits from treatment with these agents, despite unconventional patterns of tumour response that can be misinterpreted as disease progression, warranting a new, specific approach to evaluate responses to immunotherapy.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 10. Precision Genomics and Precision Medicine for Immuno Oncology:

Tumors often evade immune demolition by adapting and circumventing immune checkpoints to create resistance. This versatile insusceptibility reversed to stimulate the endogenous immune response. Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, making it able to recognize these cancer cells and destroy them. Because of the fast extension of genomic advances Precision Medicine in cancer is prompting therapeutic capabilities. By a deeper understanding of the tumour genetics, patients can be prescribed more effective therapies or even avoid those that may be potentially adverse. This webinar will feature the current renaissance in immunotherapy and discuss the expanding role of both genomics and transcriptomics in providing more personalized cancer care.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 11.  Cancer Immunology & Immunotherapy:

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways: Own immune system stimulation, Biological therapy or biotherapy. These advances in growth immunotherapy are the aftereffect of long haul interests in essential research on the immune system—research that continues today. Additional research is currently under way to: comprehend why immunotherapy is compelling in a few patients however not in other's who have a similar disease, grow the utilization of immunotherapy to more kinds of tumor, increment the viability of immunotherapy by joining it with different sorts of cancer treatment, for example, directed treatment, chemotherapy, and radiation treatment.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 12.  Technological Developments of Immuno oncology:

Kineta Immuno-Oncology is Immuno-Oncology is building up an Innovative innovation concentrated on invulnerable incitement on immune stimulation to turn cold tumors hot. Small molecule drugs that target the RIG-I (retinoic acid-inducible gene I) pathway, an effective pathway for drug discovery. The medication instrument drives tumor resistance through direct tumor cell killing and directly activation of antigen presentation cells. It strengthens tumor particular T cells population basic for finish reaction rate of different immunotherapies, for example, check point inhibitors. Novel new immunotherapies are expected to enhance long time survival in Cancer patients.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 13. Adoptive T Cell Therapy (ACT):

Verifiably, there have been three mainstays of tumor treatment: surgery, chemotherapy, and radiotherapy. In recent years, immunotherapy has developed as a conceivable fourth column, focusing on Cancer not by its anatomic area or inclination to isolate, however by the innate components the resistant framework uses to recognize sound and pathologic tissue. Adoptive T cell therapy (ACT) is one stone in this new column, a possibly capable way to deal with cancer treatment that relies on the infusion of tumor-specific T cells.

From a hypothetical point of view, Cancer immunotherapy utilizing T cells has long been of interest. Adaptive immunity has various gainful properties that make it amenable for cancer treatment: 1) T cell responses are specific, and can thus potentially distinguish between healthy and cancerous tissue; 2) T cells responses are robust, undergoing up to 1,000-fold clonal expansion after activation; 3) T cell response can traffic to the site of antigen, suggesting a mechanism for eradication of distant metastases; and 4) T cell responses have memory, maintaining therapeutic effect for many years after initial treatment.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 14. Advances in Cancer Treatment:

 The launch of multiple novel agents, coupled with increasing awareness and focus on cancer prevention, and emphasis on early diagnosis, have contributed to improved outcomes and a reduction in mortality rates for many of the major cancers over the past decade. Since 2011, 68 new drugs have been approved for 22 indications, including immuno-oncology agents that have considerably changed the treatment paradigm in many of the cancers .In particular, the immuno-oncology PD-1 and PD-L1 inhibitors have witnessed a rapid uptake based on their remarkable clinical profile and approval for multiple cancers .In an indication like melanoma, which until recently had very high unmet need and few treatment options, availability of newer treatment options has nearly tripled the number of patients receiving treatment and has nearly doubled the survival in metastatic melanoma. In non-small cell lung cancer (NSCLC), novel agents have provided improved outcomes compare to previous treatments which were less effective and more toxic.

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Track 15Tools and Trends in Immuno-Oncology:

Here are 10 current-day immuno-oncology tools and trends that are bringing this hot area of cancer treatment to the Following level.Combination therapy.

  1. Human PDX models.  
  2. The microbiome.
  3. Interrogating Immune Responses.
  4. Bioluminescence.
  5. Tumor Vaccines
  6. Cellular Therapies.
  7.  CRISPR
  8. Triple Immunodeficient Mice
  9. Integrated discovery. 
  10. Photo labelling. 

Immuno Oncology Conference |  Immuno Oncology Workshop Global Immuno Oncology Conference |  Immuno Oncology symposium |  Immuno Oncology Congress |   Immuno Oncology Seminar |  Immuno Oncology Annual Meeting American Immuno Oncology Conference |  European Immuno Oncology Conference Asian Immuno Oncology Conference

Small Molecules for Cancer Immunotherapy, April 4-5, 2018, San Diego, CA. | Annual Advances in Immuno-Oncology CongressMay 24-25  2018, London, UK | Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018, Boston, MA | Immuno-Oncology ConferenceJune 18-22, , 2018, the Westin Copley Place, Boston, Boston, USA. | Next Gen Immuno-Oncology Congress, June  21st and 22nd 2018, in Philadelphia, USA. | Immuno-Oncology 2018 World CongressJune 25–26 , 2018, Vienna, Austria. | World Congress on Oncology & Immuno Oncology, July 23-24, 2018, Amsterdam, Netherlands. | International Conference on Tumor & Cancer Immunology and Immunotherapy, September 17-18, 2018 San Diego, California USA. | Tumor Immunology and Immunotherapy, November 27-30, 2018, Loews Miami Beach Hotel, Miami Beach, Florida. | ESMO Immuno-Oncology Congress 2018Dec 13  - 16 Dec 2018,Geneva, Switzerland

Market Analysis:

About 12.7 Million cases of cancer and 7.6 million cancer death are estimated to have occurred in 2017 worldwide, with 65% deaths in the developing countries. The most familiar cancer in women is Breast Cancer, with highly survival of 85%. Prostate cancer, the tumor mostly used in Men and has global survival rate of 76%.Colorectal cancer (of the colon and rectum), with survival rate of 50-55%. Ovarian cancer depending on age has 70% survival rate between 15-44 years. Lung cancer is the threatening tumour with only 10% of survival even after been diagnosed. 

According to American Cancer Society, Cancer is the Second Most Common cause of death in the US. And accounts for nearly 1 of every 4 Deaths. The World health Organisation estimates that Worldwide there are 4 million new cancer cases and 8.2 million related in 2012.According to the World Health Organization (WHO), the numbers of new cancer cases is expected to rise by about 70% over the next 20 years

Global Data estimates that the total IO market will be approx. $14 billion in 2019, rising to $34 billion by 2024 in the 7MM(US,japan,Germany,Italy,Spain,UK and Japan).The Main drivers of this growth will come from immune check point inhibitors, which will have sales of approx. $billion in 2019,rising to $4 million by 2024.

The Highest-Selling IO Drugs by 2024 will be opdivo and keytruda,both PD-1 Inhibitors, with scales of approximately $ 10 billion and $ 7 biilion,respectively.This is because there two drugs will be first to market in many Indications leap frogging completion, Such as Roche’s Atezolizumab and Astra Zeneca Duvralemeb. Immunotherapies are the next generation in the fight against cancer, showing considerable effectiveness and lesser toxicity as compared to traditional therapy.Among various immune therapies used in cancer treatment, the most widely used ae Immune Checkpoint inhibitors, which currently accounts for over 88% of the global immune oncology market. The Market Share for immune Checkpoint is likely to reach well over 90% in the coming years, owing to their first to market Status.

Scope and importance:

Immunology deals with the study of development, anatomy functions and malfunctions of the immune system, which are fundamental to understand the human disease. The immune system is made up of many types of molecules and cells that are distributed in every tissue of the body, as well as specialized lymphoid organs, which act in a coordinated manner to prevent microbial infections, to initiate repair of damaged tissues and to suppress the growth of tumors. 

The immune system normally recognizes and responds to foreign molecules or damaged self, but not healthy host cells and tissues. The innate system of immunity is on evolutionary terms, the older system that forms the first line of defence. It is non-specific and the resistance is static. Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Leading immuno-oncology researchers are leveraging next-generation sequencing to discover biomarkers and apply genomics to personalized immunotherapy.Research into the mechanisms tumors use to evade the immune response have led to promising therapeutic targets. These therapies boost the ability of the immune system to target cancer, or limit the tumor’s ability to evade the natural immune response.

              

Target Audience

  • Immunology  and Molecular Biology Students, Scientists
  • Immunology and Biochemistry Researchers
  • Immunology, Microbiology Faculty
  • Young Researchers
  • Medical Colleges, Hospitals
  • Physicians/Consultants
  • Geneticist, Bioinformatician
  • Immunology, Cellular Biology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Manufacturing Medical Devices Companies

  Top Global Hospitals 

  • Assistance Publique Hôpitaux de Paris
  • University Clinic Heidelberg Universittsklinikum Heidelberg
  • Erasmus Medisch Centrum Universitait Medisch Centrum Rotterdam
  • Asklepios Klinikum Bad Abbach
  • Leiden University Medical Center / Leids Universitair Medisch Centrum
  • Centre Hospitalier Universitaire Vaudois Lausanne
  • Hôpitaux Universitaires de Geneve
  • Universitätsklinikum Hamburg Eppendorf
  • Universitätsklinikum und Medizinische Fakultät Tübingen
  • Sahlgrenska University Hospital

  Top Global Immunology Universities

  • Harvard University
  • University of California--San Francisco
  • Stanford University
  • Yale University
  • Johns Hopkins University
  • Washington University in St. Louis
  • Duke University
  • University of Pennsylvania
  • University of Texas Southwestern Medical Center-Dallas

Top Global Companies

  • Actelion
  • Amgen
  • AstraZeneca
  • Bayer
  • BioMarin
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Regeneron
  • Roche

 

  • Immuno-Oncology Studies
  • Cancer Biomarkers
  • Immune Checkpoint Inhibitors
  • Cancer Clinical Trials
  • Novel Approaches in Cancer & Tumor
  • Stem Cell Therapy
  • The Current Drugs Available in Immunotherapy and Combinations
  • Immune Responses Against Tumors and Transplants
  • Evaluating Response in Immunotherapy
  • Precision Genomics and Precision Medicine for Immuno Oncology
  • Cancer Immunology & Immunotherapy
  • Technological Developments of Immuno Oncology
  • Adoptive T cell therapy (ACT)
  • Advances in Cancer Treatment
  • Tools and Trends in Immuno-Oncology

2 Organizing Committee Members